BioSpace News Archive

Since an escalating number of patients are being diagnosed with cancer every day, the global demand for gene therapy and antisense drugs is bound to multiply.

In the current scenario, the competition in the global collagen market is intense, which is a reflection of a vast number of integrated players who have a strong platform of raw material suppliers.

The demand within the global market for chronic myelogenous leukaemia treatment has been rising on account of advancements in the worldwide healthcare sector.

KALYDECO® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, in children as young as 6 months of age

Dr. Reddy’s Laboratories Ltd. announces that it has completed the acquisition of select divisions of Wockhardt Limited’s branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.

Vizient, Inc. announced 12 additional drugs have been added to its essential medications list whose absence would threaten hospitals’ ability to provide high quality, timely patient care.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Richard H. Bagger to its Board of Directors, effective as of June 9, 2020. Mr. Bagger assumes the seat held by John Rhodes, who has stepped down from the position of company director that he has held since 2011. “Rich brings significant experience in healthcare having served in key senior strategi

Tanabe Research Labs and Adagene to develop a first-in-class therapeutic with a next-generation masked antibody drug conjugate (ADC), incorporating Adagene’s SAFEbody™ technology platform [10-June-2020] SAN FRANCISCO, and SUZHOU, China , and SAN DIEGO , June 10, 2020 /PRNewswire/ -- Adagene Incorporated, a precision antibody engineering, discovery and development com

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it has successfully completed development of the “change history” information and data for CypCaps™ (2 nd generation product) compared to CapCell™ (1 st generation product). The history of the

REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced it will present at the Raymond James Human Health Innovation Conference on Wednesday, June 17, 2020 , at 3:00 p.m. E